Literature DB >> 10147261

Alglucerase for Gaucher's disease: dose, costs and benefits.

E Beutler, A M Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 10147261     DOI： 10.2165/00019053-199405060-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  25 in total

1.  Enzyme replacement therapy in type I Gaucher disease.

Authors:  A C Kay; A Saven; P Garver; D W Thurston; B F Rosenbloom; E Beutler
Journal:  Trans Assoc Am Physicians       Date:  1991

Review 2.  Gaucher disease: new molecular approaches to diagnosis and treatment.

Authors:  E Beutler
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

3.  Treatment of Gaucher's disease.

Authors:  C E Hollak; J M Aerts; M H van Oers
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

4.  Treatment of Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

5.  Gaucher disease mutations in non-Jewish patients.

Authors:  E Beutler; T Gelbart
Journal:  Br J Haematol       Date:  1993-10       Impact factor: 6.998

6.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

7.  Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages.

Authors:  Y Sato; E Beutler
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Impact of home infusion therapy on the Colorado Medicaid program budget.

Authors:  V L Culbertson; R S Rhodes; E P Hill; P J Rhodes
Journal:  Am J Hosp Pharm       Date:  1988-06

9.  Gaucher disease: gene frequencies in the Ashkenazi Jewish population.

Authors:  E Beutler; N J Nguyen; M W Henneberger; J M Smolec; R A McPherson; C West; T Gelbart
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

10.  Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program.

Authors:  D N Williams; D Bosch; J Boots; J Schneider
Journal:  Clin Ther       Date:  1993 Jan-Feb       Impact factor: 3.393
View more
  7 in total

1.  Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.

Authors:  J T Clarke; D Amato; R B Deber
Journal:  CMAJ       Date:  2001-09-04       Impact factor: 8.262

2.  Alglucerase: the debate continues.

Authors:  S Push
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

3.  Evaluating the federal role in financing health-related research.

Authors:  A M Garber; P M Romer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

Review 4.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

5.  Quality of life related to type 1 Gaucher disease: Spanish experience.

Authors:  Pilar Giraldo; Victor Solano; Juan-Ignacio Pérez-Calvo; Manuel Giralt; Daniel Rubio-Félix
Journal:  Qual Life Res       Date:  2005-03       Impact factor: 4.147

6.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15

Review 7.  The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.

Authors:  Y Schuller; C E M Hollak; M Biegstraaten
Journal:  Orphanet J Rare Dis       Date:  2015-07-30       Impact factor: 4.123
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.